3 Stocks Pushing The Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 69 points (-0.4%) at 16,384 as of Monday, March 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 999 issues advancing vs. 1,928 declining with 160 unchanged.

The Health Services industry currently sits down 0.2% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Mindray Medical International Limited ADR r ( MR), down 3.3%, DexCom ( DXCM), down 3.1%, Laboratory Corporation of America Holdings ( LH), down 2.4%, Brookdale Senior Living ( BKD), down 2.3% and Alere ( ALR), down 2.3%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. St Jude Medical ( STJ) is one of the companies pushing the Health Services industry lower today. As of noon trading, St Jude Medical is down $0.43 (-0.6%) to $66.64 on average volume. Thus far, 1.2 million shares of St Jude Medical exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $66.21-$67.03 after having opened the day at $66.90 as compared to the previous trading day's close of $67.07.

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. St Jude Medical has a market cap of $19.3 billion and is part of the health care sector. Shares are up 9.7% year-to-date as of the close of trading on Friday. Currently there are 13 analysts that rate St Jude Medical a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full St Jude Medical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Can Abbott Outperform Despite Alere?

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs: Diagnosing Growth in 2017

Abbott Laboratories Can Merge With St. Jude Medical: FTC

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical